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Does screening for diabetes
in at-risk patients improve
long-term outcomes?
■ EVIDENCE-BASED ANSWER
No randomized clinical trials or prospective
studies have demonstrated adequate evidence
to screen individuals for diabetes mellitus. A
recently published meta-analysis for the United
States Preventative Services Task Force 
(USPSTF) stated that “until we have better 
evidence about its benefits, harms, and costs,
the role of screening as a strategy to reduce the
burden of suffering of diabetes will remain
uncertain” (strength of recommendation [SOR]:
B, based on inconclusive studies).
The group of patients most likely to benefit
from diabetes screening are patients with hyper-
tension (SOR: B), or those whose risk for coro-
nary heart disease is such that a diagnosis of 
diabetes would mandate addition of aspirin 
or lipid-lowering agents (SOR: C).
■ EVIDENCE SUMMARY
It is estimated that by the year 2010 approxi-
mately 216 million individuals worldwide will be
affected with diabetes; 90% of these people will
have type 2.1 In addition, it is well documented
that diabetes significantly increases the risk of
morbidity and mortality, especially due to
retinopathy, nephropathy, neuropathy, and 
coronary artery disease.2
For screening to be effective, the disease of
interest must have an easily detectable asympto-
matic state, and a treatment that improves out-
comes by intervening before symptoms develop.
Diabetes does have an asymptomatic state, which
is of uncertain duration (likely years), and is
detectable with simple, inexpensive tests: specif-
ically, either a fasting blood glucose or a 2-hour
post-glucose-load blood glucose. In order to be
useful, a screening program must also lead to an
intervention that reduces morbidity or mortality.
The data are much less clear whether any inter-
ventions during the presymptomatic period
improve patient outcomes.
No randomized trials have tested whether
screening provides any benefits.3 In a thorough
systematic review using USPSTF methodologies,
several potential postscreening interventions
were evaluated.3 While tight glycemic control
reduces progression of albuminuria and retinopa-
thy, it is unclear how large the long-term clinical
benefit would be, or at what cost. Reasonable
evidence supports more aggressive control of
blood pressure for patients with diabetes to
reduce adverse cardiovascular outcomes. It is
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baseline rate is 3% and the lead time is 2.5 years,
the NNS is 3600. 
The NNS for preventing monocular blindness is
higher, even using best-case assumptions. The
calculations for blindness rely on greater extrapo-
lations of the data; the other potential interven-
tions described above had inadequate data even to
make such calculations. 
■ RECOMMENDATIONS FROM OTHERS
The USPSTF concludes that the evidence is insuf-
ficient to recommend for or against routinely
screening asymptomatic adults for type 2 dia-
betes, impaired glucose tolerance, or impaired
fasting glucose. The USPSTF recommends
screening for type 2 diabetes in adults with hyper-
tension or hyperlipidemia. They report that it is
likely that more aggressive treatment of hyper-
tension, hyperlipidemia, and other cardiovascular
risk factors could reduce cardiovascular morbidi-
ty and mortality.4
The American Diabetes Association (ADA) rec-
ommends that health care providers consider
screening patients at age 45 years and continue
screening in 3-year intervals. The ADA also
notes that individuals who are overweight or
considered to be at higher risk should be
screened at a younger age and more frequently. 
The ADA recommends routine screening in
“high-risk” patients, defined as those with a
positive family history of type 2 diabetes (in
first- and second-degree relatives), or who are
Native Americans, African-Americans, Hispanic
Americans, or Asians/South Pacific Islanders. 
The ADA also recommends screening for
patients who have signs of insulin resistance or
conditions associated with insulin resistance,
such acanthosis nigricans, hypertension, dys-
lipidemia, and polycystic ovary syndrome. They
note that this advice is based on expert opinion
and should be carried out at the discretion of the
health care provider.5
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important to note that the data for these inter-
ventions (aggressive blood sugar and blood pres-
sure control) were derived in studies of patients
with established diabetes; no studies have tested
these interventions for patients who had early
diagnosis by screening.
Since undiagnosed diabetes doubles the risk of
coronary artery disease, there is the potential that
intervention with prophylactic aspirin and lipid-
lowering agents could reduce coronary artery dis-
ease, although this has not been tested. There is
no evidence that the diagnosis of diabetes per se
alters individual patients’ behavior in response to
lifestyle counseling, particularly about smoking
cessation, diet, and exercise. It is unlikely that
screening for foot ulcers would provide any bene-
fit in those with an early diagnosis of diabetes.
There is reasonable evidence that aggressive
counseling and behavioral interventions can
postpone the diagnosis of diabetes for patients
with glucose intolerance. The studies were too
small and short to detect any meaningful differ-
ence in morbidity or mortality. In addition, it is
unknown if this postponing of the onset of 
diabetes is cost-effective.
The risks of screening include false-positive
diagnosis, labeling effect, and subjecting patients
to potentially harmful medications. There is little
data to estimate the size of these effects.
Using a best-case scenario, the number need-
ed to screen (NNS) is 500 to prevent cardiovas-
cular outcomes by aggressive hypertension 
therapy. This assumes a baseline rate of 6%
undetected diabetes, with a 5-year lead-time 
benefit to screening, and 50% increase in the rate
of aggressive hypertension control. Assuming the
Evidence supports more aggessive
control of blood pressure 
for patients with diabetes
www.jfponline.com
C L I N I C A L  I N Q U I R I E S
MAY 2004 / VOL 53, NO 5 · The Journal of Family Practice 403
C O N T I N U E D
■ CLINICAL COMMENTARY:
Evidence for universal screening 
is not there
Many of my patients lead unhealthy lifestyles;
they become obese and often develop hyper-
tension, diabetes, dyslipidemia, and heart dis-
ease. Further, the incidence of diabetes in the
United States has grown by one third in the
last decade, and the urge to screen is great.
However, the evidence for a significant benefit
from screening for diabetes is not there. In
fact, the meta-analysis by Harris et al sug-
gests that the number needed to screen in the
most favorable group, hypertensives, would
still be 900 to prevent 1 cardiovascular event.
Furthermore, that estimate results from
extrapolation and conjecture; no randomized
controlled trial of screening for diabetes has
been done. Accordingly, the recommendations
by the ADA and USPSTF to screen high-risk
patients are likely as aggressive as can be sup-
ported at this time—regardless of the drive to
do something.
Jim Holt, MD, East Tennessee State University, 
Johnson City
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What is the best treatment
for diabetic neuropathy? 
■ EVIDENCE-BASED ANSWER
Tricyclic antidepressants, anticonvulsants, and
capsaicin reduce the pain of diabetic neuropathy;
limited data suggests that lidocaine patches may
also be efficacious. Both tricyclic antidepressants
and anticonvulsants are superior to placebo in
relieving painful diabetic neuropathy. Compared
with placebo, patients taking tricyclic antidepres-
sants report reduced pain (number needed to
treat [NNT] for at least 50% reduction=
3.5) (strength of recommendation [SOR]: A).
Similarly, patients taking anticonvulsants report
reduced pain (NNT for at least 50% reduction in
pain=2.7) (SOR: A).
Limited evidence suggests that selective sero-
tonin reuptake inhibitors (SSRIs) are no more
efficacious than placebo (SOR: C). Both anti-
depressants and anticonvulsants have a high rate
of minor adverse effects (number needed to harm
[NNH]=2.7 for both). Tricyclic antidepressants
have an NNH of 17 for side effects severe enough
that patients withdrew from the study. 
Compared with placebo, topical capsaicin also
reduces pain (NNT=4) (SOR: A); however, there
are no systematically collected data on side
effects for capsaicin. A single case series demon-
strates that lidocaine patches are efficacious for
neuropathic pain, though expensive (SOR: B).
Almost no trials comparing different classes of
treatments have been performed. 
■ EVIDENCE SUMMARY
A recent well-done meta-analysis1 summarized
available randomized placebo-controlled trials of
antidepressants (including tricyclics and SSRIs)
and anticonvulsants (including phenytoin, carba-
mazepine, and gabapentin). Almost all trials com-
pare individual agents against placebo, and there
have been no head-to-head trials that address
functional outcomes, quality of life, patient 
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